Enzyme Patterns and Factors Associated with Mortality among Patients with Carbapenem Resistant Acinetobacter Baumannii (CRAB) Bacteremia: Real World Evidence from a Tertiary Center in India

被引:0
作者
Prayag, Parikshit Shirish [1 ,5 ]
Patwardhan, Sampada A. [2 ]
Joshi, Rasika S. [1 ]
Panchakshari, Shweta P. [1 ]
Rane, Tejashree [3 ]
Prayag, Amrita P. [4 ]
机构
[1] Deenanath Mangeshkar Hosp & Res Ctr, Dept Infect Dis, Pune, India
[2] Deenanath Mangeshkar Hosp & Res Ctr, Dept Microbiol, Pune, India
[3] Deenanath Mangeshkar Hosp & Res Ctr, Dept Clin Pharmacol, Pune, India
[4] Deenanath Mangeshkar Hosp & Res Ctr, Dept house Res, Pune, India
[5] Deenanath Mangeshkar Hosp, Dept Infect Dis, Pune, India
关键词
Acinetobacter Baumannii; Acinetobacter baumannii carbapenem; Bacteremia; Carbapenem resistant Acinetobacter baumannii; Polymyxin; IN-VITRO ACTIVITY; OPEN-LABEL; INFECTIONS; COLISTIN;
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: In the Indian setting, antimicrobial resistance in A. baumannii is a considerable problem, especially in intensive care units (ICUs). Due to the limited data, clinicians are left with very few choices except polymyxins for treating serious infections caused by A. baumannii. There is sparse data regarding the local mechanisms of resistance. Given the current therapeutic challenges, it is critical to know the local enzymatic patterns and antibiograms.Materials and methods: A retrospective analysis of 50 episodes of bacteremia caused by CRAB. We analyzed the enzyme patterns and the susceptibility rates to various antibiotics.Results: The resistance rates for amikacin, tigecycline, minocycline, and fluoroquinolones were 88, 82, 50, and 88% respectively. OXA-23 was the most commonly isolated enzyme (86% of the isolates produced OXA-23) followed by OXA-51 and NDM. The overall mortality was high (58%). On univariate analysis, pneumonia, and higher Pitt's bacteremia score were significantly associated with mortality (p = 0.04 and p = 0.001 respectively). Of the total patients who received combination therapy, a majority (58%) received polymyxin plus meropenem. Combination therapy using polymyxins as a backbone was not associated with reduced mortality (p = 0.1).Conclusion:A. baumannii is associated with significant morbidity and mortality, as shown in our study. The rates of resistance for aminoglycosides were very high, and minocycline showed better susceptibility rates in comparison with tigecycline. In our study, OXA-23 and NDM remained the most important enzymes. The routine use of the combination of polymyxin and meropenem may not offer a significant advantage over monotherapy.
引用
收藏
页码:663 / 668
页数:6
相关论文
共 16 条
  • [1] [Anonymous], 2021, Annual report (January 2021 to December 2021) of the Antimicrobial Resistance Research & Surveillance Network (AMRSN), Division of epidemiology and communicable diseases, P6
  • [2] In vitro Activity of Fosfomycin against Multidrug-Resistant Urinary and Nonurinary Gram-Negative Isolates
    Behera, Bijayini
    Mohanty, Srujana
    Sahu, Subhrajyoti
    Praharaj, Ashok Kumar
    [J]. INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2018, 22 (07) : 533 - 536
  • [3] Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies
    Bosch, Xavier
    Rovira, Montserrat
    Sitges, Marta
    Domenech, Ariadna
    Ortiz-Perez, Jose T.
    de Caralt, Teresa M.
    Morales-Ruiz, Manuel
    Perea, Rosario J.
    Monzo, Mariano
    Esteve, Jordi
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (23) : 2355 - 2362
  • [4] Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii
    Chandran, Suriya
    Manokaran, Yuvasri
    Vijayakumar, Saranya
    Shankar, Baby Abirami
    Bakthavatchalam, Yamuna Devi
    Dwarakanathan, Hariharan Triplicane
    Yesudason, Binesh Lal
    Veeraraghavan, Balaji
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2023, 42 (05) : 645 - 651
  • [5] Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance
    Clark, Justin A.
    Burgess, David S.
    [J]. THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2020, 7
  • [6] ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
    Durand-Reville, Thomas F.
    Guler, Satenig
    Comita-Prevoir, Janelle
    Chen, Brendan
    Bifulco, Neil
    Hoan Huynh
    Lahiri, Sushmita
    Shapiro, Adam B.
    McLeod, Sarah M.
    Carter, Nicole M.
    Moussa, Samir H.
    Velez-Vega, Camilo
    Olivier, Nelson B.
    McLaughlin, Robert
    Gao, Ning
    Thresher, Jason
    Palmer, Tiffany
    Andrews, Beth
    Giacobbe, Robert A.
    Newman, Joseph V.
    Ehmann, David E.
    de Jonge, Boudewijn
    O'Donnell, John
    Mueller, John P.
    Tommasi, Ruben A.
    Miller, Alita A.
    [J]. NATURE MICROBIOLOGY, 2017, 2 (09):
  • [7] Hsu LY, 2017, CLIN MICROBIOL REV, V30, P1, DOI [10.1128/CMR.00042-16, 10.1128/cmr.00042-16]
  • [8] Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis
    Kengkla, Kirati
    Kongpakwattana, Khachen
    Saokaew, Surasak
    Apisarnthanarak, Anucha
    Chaiyakunapruk, Nathorn
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (01) : 22 - 32
  • [9] Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia
    Liu, Chang-Pan
    Shih, Shou-Chuan
    Wang, Nai-Yu
    Wu, Alice Y.
    Sun, Fang-Ju
    Chow, Shan-Fan
    Chen, Te-Li
    Yan, Tsong-Rong
    [J]. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2016, 49 (06) : 934 - 940
  • [10] Makris D, 2018, INDIAN J CRIT CARE M, V22, P67, DOI [10.4103/ijccm.IJCCM_302_17, 10.4103/ijccm.ijccm_302_17]